Acadia Pharmaceuticals initiates COMPASS PWS study

Acadia Pharmaceuticals announced the initiation of the Phase 3 COMPASS PWS study evaluating the efficacy and safety of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome, or PWS. PWS is a rare, neurobehavioral genetic disorder that is estimated to affect 8,000 to 10,000 patients in the United States.1-4 The most common symptom is hyperphagia, which is an unrelenting lack of satiety. Other defining features of PWS may include altered metabolism, developmental delays, behavioral challenges and moderate cognitive deficits.